Dermatology · Pittsburgh, PA
NPI
1598962078
Since 2007
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
490 E North Ave, Suite 107
Pittsburgh, PA, 15212
Phone (412) 359-3367
Groups this clinician bills Medicare through
Medicare paid, 2024
$70K
1,241 services
Medicare patients, 2024
412
Average age 71
Drug cost, 2024
$1.6M
2,671 prescriptions
Company payments, 2025
$16K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Charles E Mount III was code 99214 (office e&m - established), 242 times for 180 patients. In total Charles E Mount III billed 1,241 services in 47 codes, and Medicare paid $70K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-01-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 242 | 180 | $84.42 | $20K |
| 17003 Destruction Skin Lesion | Office | 206 | 50 | $4.51 | $930 |
| 99213 Office E&M - Established | Office | 183 | 165 | $55.58 | $10K |
| 17000 Destruction Skin Lesion | Office | 86 | 78 | $34.43 | $2,961 |
| 11102 Skin Biopsy | Office | 69 | 64 | $62.74 | $4,329 |
| 99204 Office E&M - New | Office | 57 | 57 | $120.97 | $6,895 |
| 17110 Destruction Skin Lesion | Office | 55 | 52 | $72.33 | $3,978 |
| 99203 Office E&M - New | Office | 49 | 49 | $67.41 | $3,303 |
| 11104 Skin Biopsy | Office | 35 | 35 | $86.50 | $3,027 |
| 11103 Skin Biopsy | Office | 33 | 25 | $34.59 | $1,142 |
| 99451 E&M - Miscellaneous | Facility | 16 | 14 | $27.48 | $440 |
| 11105 Skin Biopsy | Office | 15 | 13 | $45.54 | $683 |
| 11602 Skin Lesion Excision | Office | 14 | 11 | $93.54 | $1,310 |
By year: 2022 $77K for 2,085 services; 2023 $104K for 3,095 services; 2024 $70K for 1,241 services.
Medicare prescription drug claims, 2024
In 2024, the drug Charles E Mount III prescribed most often to Medicare patients was Ketoconazole, with 259 prescriptions and refills. In total Charles E Mount III wrote 2,671 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 259 | 293 | 119 | $5,838 |
| Triamcinolone Acetonide Generic | 221 | 248 | 141 | $2,744 |
| Clobetasol Propionate Generic | 141 | 151 | 70 | $6,868 |
| Prednisone Generic | 125 | 131 | 71 | $506 |
| Doxycycline Hyclate Generic | 125 | 156 | 60 | $3,288 |
| Fluorouracil Generic | 119 | 119 | 102 | $8,615 |
| Hydroxychloroquine Sulfate Generic | 119 | 194 | 25 | $4,957 |
| Hydrocortisone Generic | 113 | 117 | 62 | $385 |
| Minoxidil Generic | 103 | 200 | 27 | $726 |
| Acitretin Generic | 69 | 85 | 26 | $23K |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 67 | 68 | 27 | $2,614 |
| Dupixent Pen Dupilumab | 59 | 59 | 13 | $222K |
| Methotrexate Methotrexate Sodium | 58 | 95 | 13 | $1,132 |
| Rinvoq Upadacitinib | 57 | 63 | Under 11 | $418K |
| Fluconazole Generic | 53 | 106 | 42 | $699 |
Brand drugs: - claims; generic drugs: 2,362 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Charles E Mount III $16K ($16K in general payments such as food, travel and fees) from 14 companies. The largest payer was Abbvie Inc. with $15K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 47 | $15K |
| Janssen Biotech, Inc. JNJ | 22 | $531 |
| UCB, Inc. UCB.BR | 8 | $274 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $162 |
| Journey Medical Corporation DERM | 1 | $122 |
| Galderma Laboratories, L.P. GALD.SW | 3 | $72.57 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $58.78 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 1 | $35.48 |
| LEO Pharma Inc. | 1 | $28.17 |
| Incyte Corporation INCY | 1 | $24.94 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.